Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti–PD-1 Therapy
The comprehensive CD73 inhibition exhibited by Sym024 may improve the efficacy of anti-PD-(L)1/anti-CD73 combination treatment.
Authors
- Maria C. Melander
- Michael Monrad Grandal (ORCID: https://orcid.org/0000-0001-5434-9978)
- Isabelle Théret (ORCID: https://orcid.org/0000-0003-1283-5091)
- Janus S. Jakobsen (ORCID: https://orcid.org/0000-0001-6135-5815)
- Emily Armbruster (ORCID: https://orcid.org/0000-0001-6343-2968)
- Anne Worsaae
- Matteo Riva (ORCID: https://orcid.org/0000-0003-2697-6717)
- Johan Lantto (ORCID: https://orcid.org/0000-0002-8650-7157)
- Rikke Hald
- Harsh Bansia (ORCID: https://orcid.org/0000-0002-6738-8754)
- Amedee des Georges
- Kristian Reckzeh
- Laurent Vuillard
- Niels Jørgen Ø. Skartved
- Camilla Fröhlich
- Randi W. Hansen
Institutions
- The Graduate Center, CUNY (US)
- City University of New York (US)
- Symphogen (Denmark) (DK)
- CUNY Advanced Science Research Center (US)
- Servier (France) (FR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2406
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00